Page
%P
1 Result(s)
within
Sheng Teng
Biomedicine, general
-
Article
Open AccessPhase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the ef...
